Verge Genomics Applies Network Algorithms to Identify Drugs for ALS, AD

Verge Genomics, a new startup company out of the YCombinator accelerator program, has received $4 million in seed funding to develop its computational drug discovery platform for applications in the neurodegenerative disease space. Founded by scientists from University of California, Los Angeles, Verge uses computational network analysis to map disease-causing genes and then identify FDA-approved drugs that target those same pathways and can be repurposed. This “genomic network” approach has already yielded several candidate drugs for Alzheimer’s disease and ALS, and is at the stage of advancing these drug from early in vitro testing to preclinical testing in animal models. Stay tuned!

Click here to read more.

computational disease-ad disease-als topic-genetics topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail